| Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors B Stefanini, L Bucci, V Santi, N Reggidori, D Rampoldi, L Lani, A Granito, ... Digestive and Liver Disease 54 (11), 1563-1572, 2022 | 12 | 2022 |
| Hepatotoxicity of small molecule protein kinase inhibitors for cancer M Viganò, M La Milia, MV Grassini, N Pugliese, M De Giorgio, S Fagiuoli Cancers 15 (6), 1766, 2023 | 11 | 2023 |
| Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs N Reggidori, L Bucci, V Santi, B Stefanini, L Lani, D Rampoldi, G Ghittoni, ... JHEP Reports 5 (8), 100784, 2023 | 9 | 2023 |
| Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma EG Giannini, G Pieri, S Labanca, MCP Torres, A Gasbarrini, E Biasini, ... Digestive and Liver Disease 54 (9), 1215-1221, 2022 | 9 | 2022 |
| Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection F Pelizzaro, F Trevisani, V Simeon, A Vitale, U Cillo, F Piscaglia, ... Liver International 43 (12), 2762-2775, 2023 | 7 | 2023 |
| Vaccination recommendations in solid organ transplant adult candidates and recipients M Viganò, M Beretta, M Lepore, R Abete, SV Benatti, MV Grassini, ... Vaccines 11 (10), 1611, 2023 | 6 | 2023 |
| Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis C Celsa, G Cabibbo, DJ Pinato, G Maria, M Enea, M Vaccaro Liver Cancer 10, 000531744, 2023 | 5 | 2023 |
| The evolving scenario in the assessment of radiological response for hepatocellular carcinoma in the era of immunotherapy: Strengths and weaknesses of surrogate endpoints P Giuffrida, C Celsa, M Antonucci, M Peri, MV Grassini, G Rancatore, ... Biomedicines 10 (11), 2827, 2022 | 4 | 2022 |
| Efficacy and safety of Atezolizumab plus Bevacizumab-based sequential treatment for unresectable hepatocellular carcinoma: A simulation model C Celsa, G Cabibbo, S Battaglia, P Giuffrida, GEM Rizzo, M Grova, ... Journal of Hepatology 77, S387-S388, 2022 | 4 | 2022 |
| Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis. C Celsa, G Cabibbo, DJ Pinato, G Di Maria, M Enea, M Vaccaro, ... Liver Cancer 13 (2), 169-180, 2023 | 3 | 2023 |
| Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma EG Giannini, A Pasta, G Pieri, MC Plaz Torres, M Marseglia, F Pelizzaro, ... Liver International, 2024 | 2 | 2024 |
| T. 07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK C Celsa, G Cabibbo, R Ciccia, G Di Maria, D Pagano, R Miraglia, ... Digestive and Liver Disease 56, S258, 2024 | | 2024 |
| Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network C Celsa, G Cabibbo, R Ciccia, G Di Maria, D Pagano, R Miraglia, ... Digestive and Liver Disease 56, S83-S84, 2024 | | 2024 |
| VACCINATON POLICIES IN SOLID ORGAN TRANSPLANT ADULT CANDIDATES AND RECIPIENTS M Viganò, M Beretta, M Lepore, R Abete, SV Benatti, MV Grassini, ... Preprints, 2023 | | 2023 |
| OC. 08.2 NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: WHO IS THE WINNER? C Celsa, G Cabibbo, GEM Rizzo, P Giuffrida, G Di Maria, S Battaglia, ... Digestive and Liver Disease 55, S106, 2023 | | 2023 |
| Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: Who is the winner? C Celsa, G Cabibbo, GEM Rizzo, P Giuffrida, M Enea, G Di Maria, ... Digestive and Liver Disease 55, S3, 2023 | | 2023 |
| Outcomes of three lines Atezolizumab plus Bevacizumab-based sequential treatment for hepatocellular carcinoma: a simulation model C Celsa, G Cabibbo, S Battaglia, P Giuffrida, GEM Rizzo, M Grova, ... Digestive and Liver Disease 54, S52-S53, 2022 | | 2022 |
| The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints … P Giuffrida, C Celsa, M Antonucci, M Peri, MV Grassini, G Rancatore, ... s Note: MDPI stays neu-tral with regard to jurisdictional claims in …, 2022 | | 2022 |
